Previous 10 | Next 10 |
SAN CARLOS, Calif. , April 16, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), Cancer Research UK , Imperial College London and the University of Leicester , today announced the publication of results of a clinical study demonstrating that the Signatera...
CareDx ( CDNA +4.4% ) has filed a second lawsuit against Natera ( NTRA +3.7% ) accusing it of misleading doctors and patients about its kidney transplant technology compared to CDNA's AlloSure via its "false advertising campaign" claiming that its technology is superior to AlloSure. ...
SAN CARLOS, Calif. , April 10, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA) Natera, a leader in cell-free DNA testing, today announced plans to commercialize a research-use-only (RUO) service for whole exome sequencing (WES) of circulating tumor DNA, using plasma samples from p...
The Federal Reserve Board and the Federal Deposit Insurance Corp. say they didn't identify any deficiencies or weaknesses in the 2017 resolution plans, known as "living wills," for the 14 financial institutions evaluated. More news on: Natera, Inc., Ally Financial Inc., American Express ...
SAN CARLOS, Calif. , March 28, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that Palmetto MolDx has issued draft local coverage determination (LCD) for use of the company's new Prospera donor-derived cell-free D...
Natera ( NTRA +0.7% ) perks up on light volume on the heels of its announced collaboration with AML Therapeutics in a clinical trial evaluating the latter's therapeutic cancer vaccine candidate ATP128 in patients with stage IV colorectal cancer. More news on: Natera, Inc., Healthcare s...
SAN CARLOS, Calif. , March 26, 2019 /PRNewswire/ -- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, will partner with AMAL Therapeutics on a clinical trial focused on stage IV colorectal cancer. This study adds to the growing number of pharmaceutical tri...
Deals and Financings InventisBio of Shanghai closed a $70 million Series C financing co-led by Advantech Capital and CMBI, followed by Pudong Innotek (see story ). Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases. The co...
The following slide deck was published by Natera, Inc. in conjunction with their 2018 Q4 earnings Read more ...
Natera Inc. (NASDAQ:NTRA) shares are soaring up +20% this morning after the healthcare company released its Q4 and full 2018 earnings. The healthcare stock is seeing its biggest share rise today in well over six months. Investors seem pleased with Natera’s earnings, so if youȁ...
News, Short Squeeze, Breakout and More Instantly...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it will release results for its second quarter ended June 30, 2024, after the market close on Aug. 8, 2024. Natera will host a conference call and webcast shortly thereafter at 1:30 p.m. PT (4:30 p.m. ET...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...